<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01832961</url>
  </required_header>
  <id_info>
    <org_study_id>13/C0346</org_study_id>
    <nct_id>NCT01832961</nct_id>
  </id_info>
  <brief_title>Acute Effects of a Flutter Device in COPD</brief_title>
  <acronym>AEFLUC</acronym>
  <official_title>Acute Effects of a Flutter Device on Airways Resistance in Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation that is
      not fully reversible, and is usually progressive and associated with an abnormal inflammatory
      response of the lungs to noxious particles or gases, most commonly cigarette smoking. The
      disease affects not only the large central airways but also the small, more peripheral
      airways deeper into the lung, defined as less than 2 mm in diameter.

      Besides medical treatment, physiotherapy plays a major role in treatment and various methods
      have been suggested to remove airway of secretions. The flutter is a simple and small device
      shaped like a pipe that creates a positive expiratory pressure (PEP) and high frequency
      oscillation when the expired air passes through it. These vibrations are thought to mobilise
      airway secretions facilitating their clearance and improving breathing.

      Standard blowing tests, like spirometry, where patients blow forcedly into a machine, have
      previously been used to investigate the efficacy of flutter devices. However, spirometry
      assesses the damage of larger airways but not small airways, also known as the &quot;silent zone&quot;
      which, crucially, are specifically damaged in COPD.

      In this study the investigators hypothesise that because the flutter helps clear the airways
      from the excessive thick mucus produced by COPD patients, these patients may find it easier
      to breathe and have lower resistance to moving air in and out of their lungs.

      The main objective of this study is to compare the effect of a flutter or a sham device on
      small airways damage using impulse oscillometry (IOS), a non-invasive method that, contrary
      to other common blowing tests, measures small airway resistance during normal breathing.

      In addition, because COPD is characterised by inflammation, the investigators would also like
      to measure a gas the patients blow out, nitric oxide (NO) the levels of which reflect airway
      inflammation. This will give to investigators an insight into the relationship between airway
      inflammation and small airway function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation that is
      not fully reversible. This limitation is usually progressive and associated with an abnormal
      inflammatory response of the lungs to noxious particles or gases.

      Patients suffering from COPD may show pathologic changes not only in the large but also in
      the small airways, which are defined as less than 2mm in diameter. Airway inflammation may
      cause increased thick mucus secretions which can narrow the airways increasing the resistance
      to the airflow.

      Physiotherapy to remove secretions is indicated for patients with COPD who have regular
      sputum or those with thick secretions and various techniques and physiotherapy devices can be
      applied for the removal of secretions. The flutter is a simple and small device shaped like a
      pipe that creates a positive expiratory pressure (PEP) and high frequency oscillation as
      expired air passes through it. These vibrations and PEP are thought to mobilise airway
      secretions facilitating their clearance and improving airflow.

      The effects of the flutter device have been studied in different patient groups, but
      especially in lung diseases characterised by mucus hypersecretion such as COPD, cystic
      fibrosis and bronchiectasis. In COPD, even though the flutter device increases the volume of
      expectorated secretions, its beneficial effects on pulmonary function as assessed by
      spirometry and plethysmography are inconclusive. However, these standard lung function tests
      (such as spirometry) asses the large airways, but do not provide an accurate estimate of the
      small airways which have been described by some authors as &quot;the silent zone&quot;.

      The investigators hypothesise that the use of impulse oscillometry (IOS), a non-invasive
      technique that provides information on small airway resistance during normal breathing, may
      reveal the effect of the flutter device which may have not been accurately measured by
      spirometry in previous studies.

      In addition, the investigators would like to measure exhaled nitric oxide (NO) levels which
      reflect airway inflammation and may therefore be useful to determine the association between
      small airway disease and inflammation.

      In summary, the symptoms of patients with COPD improve following breathing exercises with a
      flutter device, however, the effect of this device on lung function is unclear. The
      investigators hypothesise that the combined use IOS and NO, would help understand and
      quantify the effects of the flutter device on the small airways disease in COPD.

      The main objective of this study is to measure the effect of a 30 minutes breathing exercise
      with a flutter device on airway resistance as assessed by impulse oscillometry in patients
      with COPD.

      The secondary objective is to investigate the association between inflammation, airway
      resistance and volume of secretions in COPD patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airways Resistance (IOS)</measure>
    <time_frame>Baseline test, after breathing exercises with flutter or flutter-sham device and after 20 minutes of rest</time_frame>
    <description>Airways resistance were measured by impulse oscillometry (IOS) method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airways Resistance (IOS) - Reactance Area (Ax)</measure>
    <time_frame>Baseline test, after breathing exercises with flutter or flutter-sham device and after 20 minutes of rest</time_frame>
    <description>Airways resistance were measured by impulse oscillometry (IOS) method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airways Resistance (IOS) - Resonant Frequency (Fres)</measure>
    <time_frame>Baseline test, after breathing exercises with flutter or flutter-sham device and after 20 minutes of rest</time_frame>
    <description>Airways resistance were measured by impulse oscillometry (IOS) method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled Nitric Oxide (FeNO)</measure>
    <time_frame>Baseline and immediately after intervention</time_frame>
    <description>Exhaled nitric oxide will be measured by chemiluminescence method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry - Forced Expiratory Volume at 1 Second (FEV1) and Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline and immediately after intervention</time_frame>
    <description>Forced expiratory volume in 1s (FEV1) and forced vital capacity (FVC) were measured using a dry wedge spirometer (Jaeger Co, Wurzburg, Germany)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough</measure>
    <time_frame>During each session</time_frame>
    <description>Number of spontaneously reported cough episodes during each visit were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretion - Volume</measure>
    <time_frame>During each session</time_frame>
    <description>Expectorated secretion volume during each visit were collected, weighted and classified with a purulence score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretion - Purulence Score</measure>
    <time_frame>In each session</time_frame>
    <description>The expectorated secretion was collected, weighted and classified with a purulence score based on a previously described numerical visual scale, which ranges from 1 (mucoid) to 5 (yellow/green).
Referee of the Purulence score: Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010;138:682-692.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>flutter valve exercises</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 minutes of breathing exercises with flutter device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flutter-sham exercises</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>30 minutes of breathing exercise with flutter-sham device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flutter valve exercises</intervention_name>
    <description>30 minutes of flutter exercises</description>
    <arm_group_label>flutter valve exercises</arm_group_label>
    <other_name>Breathing exercises with flutter device</other_name>
    <other_name>Airway clearance technique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flutter Sham exercises</intervention_name>
    <description>30 minutes of flutter-sham exercises</description>
    <arm_group_label>flutter-sham exercises</arm_group_label>
    <other_name>Breathing exercises with flutter-sham device</other_name>
    <other_name>Airway clearance technique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flutter and bronchodilator exercises</intervention_name>
    <description>Flutter + bronchodilator exercises with an interval of 3 to 5 days</description>
    <arm_group_label>flutter valve exercises</arm_group_label>
    <arm_group_label>flutter-sham exercises</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - patients with COPD meeting the Global Initiative for Obstructive Lung Disease (GOLD)
        guidelines, with forced expiratory volume in the first second of expiration (FEV1) &lt;80%
        predicted, FEV1/FVC ratio &lt;70% predicted (FVC= forced vital capacity), and total lung
        capacity (TLC) &gt;80% predicted), with or without sputum, will be included.

        The severity of COPD will be classified according to GOLD criteria:

        Stage I: mild FEV1/FVC&lt;0.70 and FEV1&gt;80% predicted; Stage II: moderate FEV1/FVC&lt;0.70 and
        50&lt;FEV1&lt;80% predicted; Stage III: severe FEV1/FVC&lt;0.70 and 30&lt;FEV1&lt;50% predicted; Stage IV:
        very severe FEV1/FVC&lt;0.70 and FEV1&lt;30% or FEV1&lt;50% predicted plus chronic respiratory
        failure,

        Exclusion Criteria:

        Patients with:

          -  Upper respiratory tract infection within the previous 28 days

          -  Treatment with antibiotics within 4 weeks prior the study

          -  Acute dyspnoea or hemoptysis

          -  Chest pain or recent history of rib fracture or pneumothorax

          -  Acute cardiovascular events in the previous 3 months

          -  Any history or evidence of renal, gastrointestinal or hepatic disease

          -  Any history and evidence of neuropsychiatric disease

          -  Alcohol, drug abuse or any other condition associated with poor compliance

          -  Breast feeding

          -  Pregnancy

          -  Other complications that hinder the completion of the tests

          -  Unable to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Usmani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma Lab, Royal Brompton Hospital, National Heart and Lung Institute, Imperial College London</name>
      <address>
        <city>London</city>
        <zip>SW3 6LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620777/</url>
    <description>Gastaldi AC, et al. Oscillating Positive Expiratory Pressure on Respiratory Resistance in Chronic Obstructive Pulmonary Disease With a Small Amount of Secretion: A Randomized Clinical Trial. Medicine (Baltimore) 2015; 94(42): 1-8.</description>
  </link>
  <results_reference>
    <citation>Gastaldi AC, Paredi P, Talwar A, Meah S, Barnes PJ, Usmani OS. Oscillating Positive Expiratory Pressure on Respiratory Resistance in Chronic Obstructive Pulmonary Disease With a Small Amount of Secretion: A Randomized Clinical Trial. Medicine (Baltimore). 2015 Oct;94(42):e1845. doi: 10.1097/MD.0000000000001845.</citation>
    <PMID>26496331</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <results_first_submitted>August 14, 2019</results_first_submitted>
  <results_first_submitted_qc>February 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2020</results_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>physiotherapy care</keyword>
  <keyword>lung function testing</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flutter Valve, Then Flutter Sham and Flutter+Bronchodilator</title>
          <description>Visit 1: medical history, physical examination and written informed consent
Visit 2: FeNO, IOS and spirometry + 30 minutes of breathing exercises with flutter device
Visit 3: FeNO, IOS and spirometry + 30 minutes of flutter-sham exercises
Visit 4: FeNO, IOS and spirometry + bronchodilator (Salbutamol) + 30 minutes of breathing exercises with flutter device</description>
        </group>
        <group group_id="P2">
          <title>Flutter Sham, Then Flutter Valve and Flutter+Bronchodilator</title>
          <description>Visit 1: medical history, physical examination and written informed consent
Visit 2: FeNO, IOS and spirometry + 30 minutes of flutter-sham exercises
Visit 3: FeNO, IOS and spirometry + 30 minutes of breathing exercises with flutter device
Visit 4: FeNO, IOS and spirometry + bronchodilator (Salbutamol) + 30 minutes of breathing exercises with flutter device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patient</title>
          <description>All volunteers had a following treatments as crossover design Visit 1: medical history, physical examination and written informed consent
Visit 2: FeNO, IOS and spirometry + 30 minutes of breathing exercises with flutter device
Visit 3: FeNO, IOS and spirometry + 30 minutes of flutter-sham exercises
Visit 4: FeNO, IOS and spirometry + bronchodilator (Salbutamol) + 30 minutes of breathing exercises with flutter device</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Airways Resistance (IOS)</title>
        <description>Airways resistance were measured by impulse oscillometry (IOS) method.</description>
        <time_frame>Baseline test, after breathing exercises with flutter or flutter-sham device and after 20 minutes of rest</time_frame>
        <population>Patients with COPD, without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis, and no recent history of rib fractures or pneumothorax.
In the Flutter-sham Control group after 20 minutes of rest - no data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Flutter Exercises Session</title>
            <description>30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O2">
            <title>Flutter+Bronchodilator Session</title>
            <description>Bronchodilator (Salbutamol) + 30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O3">
            <title>Flutter-sham - Control Group</title>
            <description>30 minutes of exercise with flutter-sham device</description>
          </group>
        </group_list>
        <measure>
          <title>Airways Resistance (IOS)</title>
          <description>Airways resistance were measured by impulse oscillometry (IOS) method.</description>
          <population>Patients with COPD, without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis, and no recent history of rib fractures or pneumothorax.
In the Flutter-sham Control group after 20 minutes of rest - no data was collected.</population>
          <units>kPa/L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>R5 (kPa/L/s) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.16"/>
                    <measurement group_id="O2" value="0.61" spread="0.28"/>
                    <measurement group_id="O3" value="0.58" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R5 (kPa/L/s) Immediately after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.21"/>
                    <measurement group_id="O2" value="0.63" spread="0.26"/>
                    <measurement group_id="O3" value="0.60" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R5 (kPa/L/s) After 20 minutes of rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.18"/>
                    <measurement group_id="O2" value="0.56" spread="0.24"/>
                    <measurement group_id="O3" value="NA" spread="NA">No data was collected from this group after 20 minuted of rest.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R20 (kPa/L/s) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.12"/>
                    <measurement group_id="O2" value="0.41" spread="0.15"/>
                    <measurement group_id="O3" value="0.40" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R20 (kPa/L/s) Immediately after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.14"/>
                    <measurement group_id="O2" value="0.42" spread="0.16"/>
                    <measurement group_id="O3" value="0.41" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R20 (kPa/L/s) After 20 minutes of rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.15"/>
                    <measurement group_id="O2" value="0.39" spread="0.14"/>
                    <measurement group_id="O3" value="NA" spread="NA">No data was collected from this group after 20 minuted of rest.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R5-R20 (kPa/L/s) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.08"/>
                    <measurement group_id="O2" value="0.20" spread="0.15"/>
                    <measurement group_id="O3" value="0.19" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R5-R20 (kPa/L/s) Immediately after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.10"/>
                    <measurement group_id="O2" value="0.21" spread="0.12"/>
                    <measurement group_id="O3" value="0.19" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R5-R20 (kPa/L/s) After 20 minutes of rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.06"/>
                    <measurement group_id="O2" value="0.18" spread="0.25"/>
                    <measurement group_id="O3" value="NA" spread="NA">No data was collected from this group after 20 minuted of rest.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X5 (kPa/L/s) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.10"/>
                    <measurement group_id="O2" value="-0.27" spread="0.15"/>
                    <measurement group_id="O3" value="-0.23" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X5 (kPa/L/s) Immediately after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.11"/>
                    <measurement group_id="O2" value="-0.25" spread="0.11"/>
                    <measurement group_id="O3" value="-0.24" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X5 (kPa/L/s) After 20 minutes of rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.10"/>
                    <measurement group_id="O2" value="-0.25" spread="0.12"/>
                    <measurement group_id="O3" value="NA" spread="NA">No data was collected from this group after 20 minuted of rest.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis compared the results: immediately after to baseline values, after 20 minutes of rest to baseline values and after 20 minutes of rest to values immediately after using Friedman's Test followed by Dunn's multiple comparison test</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman's Test</method>
            <method_desc>Friedman's test followed by Dunn's multiple comparison</method_desc>
            <other_analysis_desc>The effect of size used to calculate responsiveness and classified as small (0.2), moderate (0.5) and large (0.8).</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Airways Resistance (IOS) - Reactance Area (Ax)</title>
        <description>Airways resistance were measured by impulse oscillometry (IOS) method.</description>
        <time_frame>Baseline test, after breathing exercises with flutter or flutter-sham device and after 20 minutes of rest</time_frame>
        <population>No data was collected from the Flutter-sham Control group after 20 minutes of rest.</population>
        <group_list>
          <group group_id="O1">
            <title>Flutter Exercises Session</title>
            <description>30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O2">
            <title>Flutter+Bronchodilator Session</title>
            <description>Bronchodilator (Salbutamol) + 30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O3">
            <title>Flutter-sham - Control Group</title>
            <description>30 minutes of breathing exercises with flutter-sham device</description>
          </group>
        </group_list>
        <measure>
          <title>Airways Resistance (IOS) - Reactance Area (Ax)</title>
          <description>Airways resistance were measured by impulse oscillometry (IOS) method.</description>
          <population>No data was collected from the Flutter-sham Control group after 20 minutes of rest.</population>
          <units>kPa/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ax (kPa/L) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.17"/>
                    <measurement group_id="O2" value="-0.19" spread="0.30"/>
                    <measurement group_id="O3" value="1.89" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ax (kPa/L) Immediately after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.20"/>
                    <measurement group_id="O2" value="-0.20" spread="0.26"/>
                    <measurement group_id="O3" value="2.22" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ax (kPa/L) After 20 minutes of rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.16"/>
                    <measurement group_id="O2" value="-0.18" spread="0.26"/>
                    <measurement group_id="O3" value="NA" spread="NA">No data was collected from this group after 20 minutes of rest.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis compared the results: immediately after to baseline values, after 20 minutes of rest to baseline values and after 20 minutes of rest to values immediately after using Friedman's Test followed by Dunn's multiple comparison test</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman's Test</method>
            <other_analysis_desc>The effect size was used to calculate responsiveness and classifed as small (0.2), moderate (0.5) and large (0.8)</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Airways Resistance (IOS) - Resonant Frequency (Fres)</title>
        <description>Airways resistance were measured by impulse oscillometry (IOS) method.</description>
        <time_frame>Baseline test, after breathing exercises with flutter or flutter-sham device and after 20 minutes of rest</time_frame>
        <population>No data was collected from the Flutter-sham Control group after 20 minutes of rest.</population>
        <group_list>
          <group group_id="O1">
            <title>Flutter Exercises Session</title>
            <description>30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O2">
            <title>Flutter+Bronchodilator Session</title>
            <description>Bronchodilator (Salbutamol) + 30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O3">
            <title>Flutter-sham - Control Group</title>
            <description>30 minutes of breathing exercise with flutter-sham device</description>
          </group>
        </group_list>
        <measure>
          <title>Airways Resistance (IOS) - Resonant Frequency (Fres)</title>
          <description>Airways resistance were measured by impulse oscillometry (IOS) method.</description>
          <population>No data was collected from the Flutter-sham Control group after 20 minutes of rest.</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fres (Hz) Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.95" spread="4.03"/>
                    <measurement group_id="O2" value="22.54" spread="7.70"/>
                    <measurement group_id="O3" value="22.13" spread="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fres (Hz) Immediately after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.15" spread="4.78"/>
                    <measurement group_id="O2" value="23.49" spread="6.14"/>
                    <measurement group_id="O3" value="22.41" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fres (Hz) After 20 minutes of rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.24" spread="4.29"/>
                    <measurement group_id="O2" value="21.85" spread="7.01"/>
                    <measurement group_id="O3" value="NA" spread="NA">No data was collect from this group after 20 minutes of rest.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis compared the results: immediately after to baseline values, after 20 minutes of rest to baseline values and after 20 minutes of rest to values immediately after using Friedman's Test followed by Dunn's multiple comparison test</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman's Test</method>
            <other_analysis_desc>The effect size was used to calculate responsiveness and classifed as small (0.2), moderate (0.5) and large (0.8)</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exhaled Nitric Oxide (FeNO)</title>
        <description>Exhaled nitric oxide will be measured by chemiluminescence method.</description>
        <time_frame>Baseline and immediately after intervention</time_frame>
        <population>Patients with COPD, without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of rib fracture or pneumothorax.</population>
        <group_list>
          <group group_id="O1">
            <title>Flutter Exercises</title>
            <description>Flutter exercises: 30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O2">
            <title>Flutter-sham</title>
            <description>Flutter-sham: 30 minutes of flutter-sham exercises</description>
          </group>
          <group group_id="O3">
            <title>Flutter+Bronchodilator</title>
            <description>Flutter+bronchodilator: Bronchodilator (Salbutamol) + 30 minutes of breathing exercises with flutter device</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Nitric Oxide (FeNO)</title>
          <description>Exhaled nitric oxide will be measured by chemiluminescence method.</description>
          <population>Patients with COPD, without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of rib fracture or pneumothorax.</population>
          <units>parts per billion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" spread="29.9"/>
                    <measurement group_id="O2" value="44.4" spread="33.7"/>
                    <measurement group_id="O3" value="32.3" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="33.7"/>
                    <measurement group_id="O2" value="43.6" spread="33.2"/>
                    <measurement group_id="O3" value="31.7" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>T-test</method>
            <method_desc>T-test was used to comparisons before and after FeNO results</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spirometry - Forced Expiratory Volume at 1 Second (FEV1) and Forced Vital Capacity (FVC)</title>
        <description>Forced expiratory volume in 1s (FEV1) and forced vital capacity (FVC) were measured using a dry wedge spirometer (Jaeger Co, Wurzburg, Germany)</description>
        <time_frame>Baseline and immediately after intervention</time_frame>
        <population>Patients with COPD, without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of rib fracture or pneumothorax.</population>
        <group_list>
          <group group_id="O1">
            <title>Flutter Exercises</title>
            <description>Flutter exercises: 30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O2">
            <title>Flutter-sham</title>
            <description>Flutter-sham: 30 minutes of flutter-sham exercises</description>
          </group>
          <group group_id="O3">
            <title>Flutter+Bronchodilator</title>
            <description>Flutter+bronchodilator: Bronchodilator (Salbutamol) + 30 minutes of breathing exercises with flutter device</description>
          </group>
        </group_list>
        <measure>
          <title>Spirometry - Forced Expiratory Volume at 1 Second (FEV1) and Forced Vital Capacity (FVC)</title>
          <description>Forced expiratory volume in 1s (FEV1) and forced vital capacity (FVC) were measured using a dry wedge spirometer (Jaeger Co, Wurzburg, Germany)</description>
          <population>Patients with COPD, without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of rib fracture or pneumothorax.</population>
          <units>percent predicted spirometry assessment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline FVC (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.4" spread="18.4"/>
                    <measurement group_id="O2" value="109.8" spread="19.6"/>
                    <measurement group_id="O3" value="105.8" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After intervention FVC (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.3" spread="18.1"/>
                    <measurement group_id="O2" value="109.0" spread="17.5"/>
                    <measurement group_id="O3" value="102.1" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline FEV1 (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6" spread="17.7"/>
                    <measurement group_id="O2" value="67.0" spread="17.3"/>
                    <measurement group_id="O3" value="62.1" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After intervention FEV1 (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" spread="15.5"/>
                    <measurement group_id="O2" value="65.3" spread="14.6"/>
                    <measurement group_id="O3" value="60.3" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline FEV1/FVC (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" spread="13.0"/>
                    <measurement group_id="O2" value="50.3" spread="12.0"/>
                    <measurement group_id="O3" value="48.5" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After intervention FEV1/FVC (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" spread="12.5"/>
                    <measurement group_id="O2" value="49.7" spread="10.8"/>
                    <measurement group_id="O3" value="48.9" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline MEF 25-75 (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.93" spread="8.0"/>
                    <measurement group_id="O2" value="17.8" spread="6.8"/>
                    <measurement group_id="O3" value="15.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After intervention MEF 25-75 (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="7.1"/>
                    <measurement group_id="O2" value="17.6" spread="6.9"/>
                    <measurement group_id="O3" value="15.1" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>T-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cough</title>
        <description>Number of spontaneously reported cough episodes during each visit were collected.</description>
        <time_frame>During each session</time_frame>
        <population>Patients with COPD, without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of rib fracture or pneumothorax.</population>
        <group_list>
          <group group_id="O1">
            <title>Flutter Exercises Session</title>
            <description>30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O2">
            <title>Flutter-sham Exercises Session</title>
            <description>30 minutes of breathing exercises with a flutter-sham device</description>
          </group>
          <group group_id="O3">
            <title>Flutter+Bronchodilator Session</title>
            <description>Pretreatment with a short-acting bronchodilator and 01 hour later they performed flutter exercises during 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Cough</title>
          <description>Number of spontaneously reported cough episodes during each visit were collected.</description>
          <population>Patients with COPD, without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of rib fracture or pneumothorax.</population>
          <units>Coughs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" spread="2.41"/>
                    <measurement group_id="O2" value="1.69" spread="1.49"/>
                    <measurement group_id="O3" value="3.63" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secretion - Volume</title>
        <description>Expectorated secretion volume during each visit were collected, weighted and classified with a purulence score.</description>
        <time_frame>During each session</time_frame>
        <population>COPD patients without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of a rib fracture or pneumothorax
The volume fo secretion was obtained only for two groups: Flutter exercises and flutter-sham exercises.</population>
        <group_list>
          <group group_id="O1">
            <title>Flutter Exercises Session</title>
            <description>30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O2">
            <title>Flutter-sham Exercises Session</title>
            <description>30 minutes of breathing exercises with a flutter-sham device</description>
          </group>
        </group_list>
        <measure>
          <title>Secretion - Volume</title>
          <description>Expectorated secretion volume during each visit were collected, weighted and classified with a purulence score.</description>
          <population>COPD patients without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of a rib fracture or pneumothorax
The volume fo secretion was obtained only for two groups: Flutter exercises and flutter-sham exercises.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="1.39"/>
                    <measurement group_id="O2" value="1.5" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secretion - Purulence Score</title>
        <description>The expectorated secretion was collected, weighted and classified with a purulence score based on a previously described numerical visual scale, which ranges from 1 (mucoid) to 5 (yellow/green).
Referee of the Purulence score: Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010;138:682-692.</description>
        <time_frame>In each session</time_frame>
        <population>COPD patients without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of a rib fracture or pneumothorax.</population>
        <group_list>
          <group group_id="O1">
            <title>Flutter Exercises Session</title>
            <description>30 minutes of breathing exercises with flutter device</description>
          </group>
          <group group_id="O2">
            <title>Flutter-sham Exercises Session</title>
            <description>30 minutes of breathing exercises with a flutter-sham device</description>
          </group>
          <group group_id="O3">
            <title>Flutter+Bronchodilator Session</title>
            <description>Pretreatment with a short-acting bronchodilator and 01 hour later they performed flutter exercises during 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Secretion - Purulence Score</title>
          <description>The expectorated secretion was collected, weighted and classified with a purulence score based on a previously described numerical visual scale, which ranges from 1 (mucoid) to 5 (yellow/green).
Referee of the Purulence score: Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010;138:682-692.</description>
          <population>COPD patients without upper respiratory tract infection or treatment with antibiotics within 4 weeks prior the study; without acute dyspnea or hemoptysis and no recent history of a rib fracture or pneumothorax.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="0.82"/>
                    <measurement group_id="O2" value="2.57" spread="0.79"/>
                    <measurement group_id="O3" value="2.60" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Flutter Exercises</title>
          <description>Flutter exercises: 30 minutes of breathing exercises with flutter device</description>
        </group>
        <group group_id="E2">
          <title>Flutter-sham</title>
          <description>Flutter-sham: 30 minutes of flutter-sham exercises</description>
        </group>
        <group group_id="E3">
          <title>Flutter+Bronchodilator</title>
          <description>Flutter+bronchodilator: Bronchodilator (Salbutamol) + 30 minutes of breathing exercises with flutter device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Absence of some objective measurement of dyspnea, well being or satisfaction scales.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ada Clarice Gastaldi</name_or_title>
      <organization>Imperial College</organization>
      <phone>55 020 7351 8051</phone>
      <email>ada@fmrp.usp.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

